Skip to content

Study · Randomized controlled trial · n = 54 · 2022

7 results

Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.

Vukajlovic T, Sailer CO, Asmar A, Jensen BL, Vogt DR, Christ-Crain M, Winzeler B

The Journal of clinical endocrinology and metabolism1 May 2022Cited by 3 (Europe PMC)

PMID35134170 (opens in a new tab)DOI10.1210/clinem/dgac063 (opens in a new tab)PepBankPUB-35134170
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In euvolemic participants, dulaglutide did not change plasma renin versus placebo.

    In plain wordsDulaglutide did not change blood renin compared with placebo in euvolemic participants.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changePlasma renin
    Study

    n = 54

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    After a 3-week treatment phase, dulaglutide showed no effect on plasma renin, plasma ANG II, or plasma aldosterone levels in comparison to placebo.
    2 context sentences
    Summary · context
    Randomized, double-blinded, placebo-controlled, crossover trials were conducted at University Hospital Basel, Switzerland.
    Summary · context
    A total of 54 euvolemic participants, including 20 healthy individuals and 34 patients with primary polydipsia, received a subcutaneous injection of dulaglutide (Trulicity) 1.5 mg and placebo (0.9% sodium chloride) once weekly over a 3-week treatment phase.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In euvolemic participants, dulaglutide did not change plasma angiotensin II versus placebo.

    In plain wordsDulaglutide did not change blood angiotensin II compared with placebo in euvolemic participants.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changePlasma angiotensin II
    Study

    n = 54

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    After a 3-week treatment phase, dulaglutide showed no effect on plasma renin, plasma ANG II, or plasma aldosterone levels in comparison to placebo.
    2 context sentences
    Summary · context
    Randomized, double-blinded, placebo-controlled, crossover trials were conducted at University Hospital Basel, Switzerland.
    Summary · context
    A total of 54 euvolemic participants, including 20 healthy individuals and 34 patients with primary polydipsia, received a subcutaneous injection of dulaglutide (Trulicity) 1.5 mg and placebo (0.9% sodium chloride) once weekly over a 3-week treatment phase.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In euvolemic participants, dulaglutide did not change plasma aldosterone versus placebo.

    In plain wordsDulaglutide did not change blood aldosterone compared with placebo in euvolemic participants.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changePlasma aldosterone
    Study

    n = 54

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    After a 3-week treatment phase, dulaglutide showed no effect on plasma renin, plasma ANG II, or plasma aldosterone levels in comparison to placebo.
    2 context sentences
    Summary · context
    Randomized, double-blinded, placebo-controlled, crossover trials were conducted at University Hospital Basel, Switzerland.
    Summary · context
    A total of 54 euvolemic participants, including 20 healthy individuals and 34 patients with primary polydipsia, received a subcutaneous injection of dulaglutide (Trulicity) 1.5 mg and placebo (0.9% sodium chloride) once weekly over a 3-week treatment phase.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In euvolemic participants, natriuresis remained unchanged or decreased with dulaglutide, depending on the measured parameter.

    In plain wordsCompared with placebo, dulaglutide left sodium excretion unchanged or decreased it, depending on the measurement.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    MixedNatriuresis
    Study

    n = 54

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Natriuresis remained unchanged or decreased on dulaglutide depending on the measured parameter.
    2 context sentences
    Summary · context
    Randomized, double-blinded, placebo-controlled, crossover trials were conducted at University Hospital Basel, Switzerland.
    Summary · context
    A total of 54 euvolemic participants, including 20 healthy individuals and 34 patients with primary polydipsia, received a subcutaneous injection of dulaglutide (Trulicity) 1.5 mg and placebo (0.9% sodium chloride) once weekly over a 3-week treatment phase.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In euvolemic participants, dulaglutide significantly decreased plasma MR-proANP versus placebo.

    In plain wordsDulaglutide lowered blood MR-proANP compared with placebo in euvolemic participants.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasePlasma MR-proANP
    Study

    n = 54

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Measurements

    Treatment effect
    10.6 pmol/L
    plasma MR-proANP versus placebo, as written in source
    95% CI of treatment effect
    −14.7 to −7.9 pmol/L
    plasma MR-proANP

    Source sentences

    Summary
    Dulaglutide significantly decreased plasma MR-proANP levels (treatment effect: 10.60 pmol/L; 95% CI, -14.70 to -7.90; P < .001)
    2 context sentences
    Summary · context
    Randomized, double-blinded, placebo-controlled, crossover trials were conducted at University Hospital Basel, Switzerland.
    Summary · context
    A total of 54 euvolemic participants, including 20 healthy individuals and 34 patients with primary polydipsia, received a subcutaneous injection of dulaglutide (Trulicity) 1.5 mg and placebo (0.9% sodium chloride) once weekly over a 3-week treatment phase.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In euvolemic participants, dulaglutide significantly decreased systolic blood pressure versus placebo.

    In plain wordsDulaglutide lowered systolic blood pressure compared with placebo in euvolemic participants.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseSystolic blood pressure
    Study

    n = 54

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Measurements

    Median treatment effect
    3 mm Hg
    systolic blood pressure versus placebo, as written in source
    95% CI of median effect
    −5 to 0 mm Hg
    systolic blood pressure

    Source sentences

    Summary
    systolic blood pressure (median: 3 mm Hg; 95% CI, -5 to 0; P = .036)
    2 context sentences
    Summary · context
    Randomized, double-blinded, placebo-controlled, crossover trials were conducted at University Hospital Basel, Switzerland.
    Summary · context
    A total of 54 euvolemic participants, including 20 healthy individuals and 34 patients with primary polydipsia, received a subcutaneous injection of dulaglutide (Trulicity) 1.5 mg and placebo (0.9% sodium chloride) once weekly over a 3-week treatment phase.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In euvolemic participants, dulaglutide significantly increased heart rate versus placebo.

    In plain wordsDulaglutide increased heart rate compared with placebo in euvolemic participants.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHeart rate
    Study

    n = 54

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Measurements

    Median treatment effect
    5 bpm
    heart rate versus placebo
    95% CI of median effect
    3 to 11 bpm
    heart rate

    Source sentences

    Summary
    whereas heart rate increased (median: 5 bpm; 95% CI, 3-11; P < .001).
    2 context sentences
    Summary · context
    Randomized, double-blinded, placebo-controlled, crossover trials were conducted at University Hospital Basel, Switzerland.
    Summary · context
    A total of 54 euvolemic participants, including 20 healthy individuals and 34 patients with primary polydipsia, received a subcutaneous injection of dulaglutide (Trulicity) 1.5 mg and placebo (0.9% sodium chloride) once weekly over a 3-week treatment phase.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT03141632

Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake

University Hospital, Basel, Switzerlandn = 1717 Oct 2016 to 12 May 2017

Thirst · Water-Electrolyte Imbalance

Trial pageClinicalTrials.govUpdated 25 Oct 2017
CompletedPhase 2NCT02770885

Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)

University Hospital, Basel, Switzerlandn = 50Mar 2016 to 7 Oct 2019

Primary Polydipsia

Trial pageClinicalTrials.govUpdated 18 Jan 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.